GlobeNewswire Inc.Apr 18, 1:31 PM ET▲ Positive
The company announced encouraging clinical trial results showing deep and durable tumor responses (89% average reduction), extended median time on treatment (19 months), and successful biomarker validation (IFN-γ increases). The drug was well-tolerated with manageable adverse events. The initiation of Phase 1b expansion trials and expected interim data in 2027 demonstrate progress in development, supporting positive momentum for the lead program.